This surgery is usually encouraged at or just before the main ovarian cancer risk period starts at 35 to 40 years for BRCA1 and 40 to 45 years for BRCA2. 10Female carriers of PVs in BRCA1/2 undertaking RRBSO have increased life expectancy mainly due to reduction in ovarian cancer risk, although there may be some reduction in breast cancer risk and reduced mortality from previous breast cancer.11, 12, 13. This evidence concerns the gene BRCA1 and ovarian cancer.